Broad deterioration beneath the surface keeps meaningful US large-cap exposure premature despite selective growth setups. Deepvue's breadth dashboard puts 56% of stocks in Stage 4 declines, while Friday saw 498 new lows against 170 new highs. A handful of medical/healthcare and software leaders can be tested in positions of 3%-5% of portfolio equity, but total exposure has a 15% hard ceiling, not a target. Adding depends on those leaders following through, better market conditions and results. x.comÂ